Weitere Suchergebnisse zu "Biogen":
 Aktien      Zertifikate      OS    

Biogen Presents New Data From Phase 3 ENDEAR Study Of SPINRAZA

13.01.17 14:02

WESTON (dpa-AFX) - Biogen (BIIB) presented new data from the Phase 3 ENDEAR study of SPINRAZA (nusinersen), which demonstrated a statistically significant reduction in the risk of death or permanent ventilation in SPINRAZA-treated infants with spinal muscular atrophy or SMA compared to untreated infants.

In August 2016, Biogen reported that ENDEAR met its pre-specified primary endpoint at the interim analysis, the proportion of motor milestone responders as measured by the Hammersmith Infant Neurological Examination (HINE). Following the positive interim analysis, Biogen ended the study early so that all participants could have the option to receive SPINRAZA in an open-label extension study.

Today, Biogen provided the first presentation of the pre-specified primary endpoint, time to death or permanent ventilation, from the end of study (EOS) analysis. The EOS results presented at BPNA include data from patients' final study visit, which occurred after the announcement that the study was being stopped and was not part of the interim analysis.

SPINRAZA met the pre-specified primary endpoint at the ENDEAR EOS, demonstrating a statistically significant 47% reduction in the risk of death or permanent ventilation (p<0.01). In the EOS analysis, a greater percentage of untreated infants (68%) died or required permanent ventilation compared to infants treated with SPINRAZA (39%).

SPINRAZA demonstrated a favorable safety profile, with commonly reported adverse events including respiratory events and constipation, consistent with those expected in the general population of infants with SMA. Further EOS efficacy and safety results from ENDEAR will be presented at a future medical congress.

Copyright RTT News/dpa-AFX


hier klicken zur Chartansicht

Aktuelle Kursinformationen mehr >
Kurs Vortag Veränderung Datum/Zeit
309,06 $ 309,46 $ -0,40 $ -0,13% 21.11./23:03
ISIN WKN Jahreshoch Jahrestief
US09062X1037 789617 348,84 $ 244,28 $
Handelsplatz Letzter Veränderung  Zeit
Tradegate (RT)
263,44 € -0,25%  21.11.17
Nasdaq 309,06 $ -0,13%  21.11.17
Stuttgart 263,18 € -0,66%  21.11.17
Berlin 263,39 € -0,71%  21.11.17
Xetra 263,30 € -0,72%  21.11.17
Frankfurt 262,478 € -0,82%  21.11.17
München 262,37 € -0,87%  21.11.17
Düsseldorf 262,27 € -0,91%  21.11.17
Hamburg 262,27 € -0,92%  21.11.17
Hannover 262,27 € -0,92%  21.11.17
  = Realtime
Aktien des Tages

Mit der Anmeldung für den Newsletter "Aktien des Tages" stimme ich dem gleichzeitigen Erhalt des "GeVestor täglich" unseres Partners GeVestor zu.

Mit der Anmeldung für den Newsletter "Aktien des Tages" stimme ich dem gleichzeitigen Erhalt des "Investors Daily" unseres Partners FID Verlag zu.

Meistgelesene Artikel
Aktuelle Diskussionen
Antw. Thema Zeit
30 Biogen - Outperform / Kursziel. 14.09.17
1 BIOGEN (789617) - Ein Trump. 18.01.17
6 Biogen 27.10.15
12 Biogen Idec Inc. - Thread! 22.03.15
11 Biogen Idec - Kursziel 260$ 23.01.15
RSS Feeds

Bitte warten...